NOVA301 | The first Phase 3 randomised clinical trial of an investigational mRNA norovirus vaccine.

The Nova 301 trial is a Phase 3 randomised, observer-blind, placebo-controlled trial evaluating the efficacy, safety and immunogenicity of mRNA-1403. The trial aims to enrol approximately 25,000 participants 18 years of age and older globally. This includes countries in the Northern Hemisphere (U.S., Canada, UK, Japan), the equatorial region, and the Southern Hemisphere (Australia and countries in South America). Approximately 20,000 participants 60 years of age and older and 5,000 participants between 18 and 59 years of age will be enrolled. The aim is to assess the vaccine’s ability to protect against moderate to severe norovirus acute gastroenteritis (AGE) in adults.

It is estimated that this virus costs the tax payer £100 million a year.

We invited over 4,600 of our patients aged 70 years and older by text message and / or email to this important research study. Those who were interested followed the link in the communications, which took them to the next stage.

For more information on this study, please click here.

DaRe2THINK is a transformational project that will test a new way of running clinical trials at General Practices in the NHS.

The trial will use health information already collected in the NHS to reduce the time taken for research, both for patients and NHS staff. This will allow the NHS to reach new and larger groups of patients that could benefit from new treatments.

The first trial will target an important health concern, aiming to improve the health outcomes of patients with atrial fibrillation (AF), by reducing the risk of stroke, blood clots and potentially cognitive decline and vascular dementia.

DaRe2THINK is funded by the National Institute of Health Research (NIHR) Health Technology Assessment programme. The trial brings together world leading expertise from:

For more information on this study, please click here.